The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000656336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
23/04/2026
Date registered
Help: Date registered
3/06/2026
Date last updated
Help: Date last updated
3/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
3/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effect of mussel salts and mussel oil on plasma plasma fatty acid levels in healthy adults
Scientific title
A randomised cross-over trial to assess the bio-equivalence of mussel salts and mussel oil on plasma plasma fatty acid levels in healthy adults
Additional trial identifiers [1] 317096 0
MBCRC340
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
plasma fatty acid metabolism 341633 0
Condition category
Condition code
Diet and Nutrition 337722 337722 0 0
Other diet and nutrition disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a randomised cross-over dietary intervention trial. The intervention will compare Greenshell Mussel (GSM) (Perna canaliculus) oil and GSM salts (powder) on plasma fatty acid levels. Each 5gm supplement will contain around 1.5 grams of omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Each supplement (5g powder, 5g oil) will be incorporated into a beverage: either juice or a diet soft drink by the study staff. The beverage will be mixed thoroughly and consumed immediately by the participant.
The supplements will be prepared by the study staff by dissolving the powder and mixed thoroughly in the beverage
The intervention will be conducted by a dietitian and a nurse with clinical trial expertise and certification in good clinical practice (nurse).
The intervention will be delivered face-to-face at the Clinical Trials Facility at Adelaide University.
Twenty participants will attend the clinic on two occasions (over three weeks) each for approximately 9-9 1/2 hours. The visits will be separated by a one-two-week washout period.
Participants will attend the clinic each occasion after an overnight fast and weight, height, blood pressure, and heart rate will be measured.
A cannula will be inserted into participants forearm for the blood tests. One blood sample will be taken, then participants will consume the dietary supplement they have been randomised to start with (oil or powder). Participants will then consumed a low fat breakfast.

Nine samples of blood will be taken at the following times after the first blood draw (time 0) : 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours.
Participants will be provided with a comfortable recliner chair, access to TV, magazines as well as snacks, lunch and a frozen meal at the end of their visit.

One to two weeks later, participants will return to the clinic to repeat the same process with the other supplement (oil or powder).

Intervention code [1] 333855 0
Lifestyle
Description of the comparator or control
This is a cross-over study where mussel oil will be compared with mussel salts (powder) on plasma fatty acid status. Participants will consume both supplements. Participants will commence with either the mussel oil or the mussel powder (salt). Participants will act as their own control.
Control group
Active

Outcomes
Primary outcome [1] 345189 0
Plasma fatty acid levels of eicosapentaenoic acid, as measured by % total fatty acids micrograms / mL plasma total area under the concentration curve (AUC) for eicosapentaenoic acid, incremental area under the concentration curve (AUC) for eicosapentaenoic acid
Timepoint [1] 345189 0
Baseline and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after the supplement is consumed in each crossover period.
Primary outcome [2] 345267 0
Plasma fatty acid levels of docosahexaenoic acid, as measured by % total fatty acids micrograms / mL plasma total area under the concentration curve (AUC) for docosahexaenoic acid, incremental area under the concentration curve (AUC) for docosahexaenoic acid
Timepoint [2] 345267 0
Baseline and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after the supplement is consumed in each crossover period.
Primary outcome [3] 345268 0
composite measure of plasma levels of Saturated fatty acids: 14:0 (myristic acid), 16:0 (palmitic acid), 18:0 (stearic acid), 24:0 (tetracosanoic acid) as measured by % total fatty acids micrograms / mL plasma total area under the concentration curve (AUC) for total saturated fatty acids incremental area under the concentration curve (AUC) for total saturated fatty acids
Timepoint [3] 345268 0
Baseline and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after the supplement is consumed in each crossover period.
Secondary outcome [1] 460811 0
composite measure of plasma levels of Monounsaturated fatty acids: 16:1n-7 (palmitoleic acid), 18:1n-9 (oleic acid), 24:1n-9 (nervonic acid) as measured by % total fatty acids micrograms / mL plasma total area under the concentration curve (AUC) for total monounsaturated fatty acids incremental area under the concentration curve (AUC) for total monounsaturated fatty acids
Timepoint [1] 460811 0
Baseline and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after the supplement is consumed in each crossover period.
Secondary outcome [2] 460814 0
Safety
Timepoint [2] 460814 0
At baseline of the first visit and the last blood of the second visit.
Secondary outcome [3] 461140 0
Composite measure of plasma levels of Polyunsaturated fatty acids: 18:2n-6 (linoleic acid), 18:3n-6 (gamma-linolenic acid), 18:3n-3 (alpha linolenic acid), 20:2n-6 (eicosadienoic acid), 20:3n-6 (dihomo-gamma-linolenic acid), 20:4n-6 (arachidonic acid), 20:5n-3 (eicosapentaenoic acid), 22:4n-6 (docosatetraenoic acid), 22:5n-3 (docosapentaenoic acid), 22:5n-6 (docosapentaenoic acid), 22:6n-3 (docosahexaenoic acid) as measured by % total fatty acids micrograms / mL plasma total area under the concentration curve (AUC) for total polyunsaturated fatty acids, incremental area under the concentration curve (AUC) for total polyunsaturated fatty acids
Timepoint [3] 461140 0
Baseline and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after the supplement is consumed in each crossover period.
Secondary outcome [4] 461141 0
Composite measure of plasma levels of Omega-6 Polyunsaturated fatty acids: 18:2n-6 (linoleic acid), 18:3n-6 (gamma-linolenic acid), 20:2n-6 (eicosadienoic acid), 20:3n-6 (dihomo-gamma-linolenic acid), 20:4n-6 (arachidonic acid), 22:4n-6 (docosatetraenoic acid), 22:5n-6 (docosapentaenoic acid) as measured by % total fatty acids micrograms / mL plasma total area under the concentration curve (AUC) for total omega-6 polyunsaturated fatty acids, incremental area under the concentration curve (AUC) for total omega-6 polyunsaturated fatty acids,
Timepoint [4] 461141 0
Baseline and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after the supplement is consumed in each crossover period.
Secondary outcome [5] 461142 0
Intolerance or gastrointestinal upset
Timepoint [5] 461142 0
Over the course of the visit (from baseline to end of blood sampling) in each crossover period.
Secondary outcome [6] 461919 0
Composite measure of plasma levels of total omega-3 Polyunsaturated fatty acids: 18:3n-3 (alpha linolenic acid), 20:5n-3 (eicosapentaenoic acid), 22:5n-3 (docosapentaenoic acid), 22:6n-3 (docosahexaenoic acid) as measured by % total fatty acids micrograms / mL plasma total area under the concentration curve (AUC) for total omega-3 polyunsaturated fatty acids, incremental area under the concentration curve (AUC) for total omega-3 polyunsaturated fatty acids
Timepoint [6] 461919 0
Baseline and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after the supplement is consumed in each crossover period.
Secondary outcome [7] 461920 0
Plasma fatty acid levels of eicosapentaenoic acid + docosahexaenoic acid, as measured by % total fatty acids micrograms / mL plasma total area under the concentration curve (AUC) for eicosapentaenoic acid + docosahexaenoic acid, incremental area under the concentration curve (AUC) for eicosapentaenoic acid + docosahexaenoic acid
Timepoint [7] 461920 0
Baseline and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after the supplement is consumed in each crossover period.

Eligibility
Key inclusion criteria
1. Aged 18–70 years at screening
2. Able and willing to provide written informed consent
3. In good general health, as determined by a medical history review
4. Body mass index between 20-35kg/m2
5. Fluent in written and spoken English
6. Have access to a General Practitioner (GP) in Australia during the study period
7. Able and willing to comply with all study requirements, including:
• Fasting overnight prior to the clinic visit
• Completing clinical assessments
• Providing blood samples
• Consuming the study supplement as directed
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
1. Have any chronic medical condition (e.g. CVD, diabetes, high blood pressure or cholesterol) or cancer within the last 2 years
2. Taking blood pressure or cholesterol or related heart medications
3. Have gastrointestinal problems
4. Have an allergy to fish or shellfish or marine products
5. Are a smoker
6. Are pregnant or lactating
7. Have high consumption of any omega-3 fatty acid or other lipid supplements
8. Are participating in any other clinical trial or dietary intervention within 90 days prior to screening or during the study period
9. Have donated blood within 7 days prior to screening, or unwillingness to abstain from blood donation for at least 7 days after the clinic visit
10. Have any other condition or circumstance that, in the opinion of the investigator, may make the participant unsafe for the study

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be conducted using sealed opaque envelopes
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomised by minimisation.
Participants will be stratified on sex, age and BMI.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Bio-equivalence
Statistical methods / analysis
Comparison of response (peak) of treatment groups - the area under the plasma concentration-time curve (both the total area under the concentration curve (AUC) and the incremental area under the concentration curve (IAUC)) from baseline up to the last measurement (t10) will be calculated.

MANOVA (2 factor analysis) – analysis of time x oil effect (the differences in measurements % fatty acids) over all time points between all treatment groups.

One-way ANOVA with repeated measures – to analyse the trend over time (9 time-points) and for testing the difference from 0 within each treatment group.
Paired t-tests – to analyse the change from t0 to all other time points within each treatment group. Two-tailed, p < .05 will be considered statistically significant

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 321684 0
Other Collaborative groups
Name [1] 321684 0
Marine Bioproducts Cooperative Research Centre
Country [1] 321684 0
Australia
Primary sponsor type
University
Name
Adelaide University
Address
Country
Australia
Secondary sponsor category [1] 324511 0
Commercial sector/Industry
Name [1] 324511 0
Natural Extraction Technologies (NE Tech)
Address [1] 324511 0
Country [1] 324511 0
New Zealand

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320217 0
Adelaide University Human Research Ethics Committee
Ethics committee address [1] 320217 0
Ethics committee country [1] 320217 0
Australia
Date submitted for ethics approval [1] 320217 0
18/09/2025
Approval date [1] 320217 0
21/04/2026
Ethics approval number [1] 320217 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149794 0
A/Prof Karen Murphy
Address 149794 0
Adelaide University, Allied Health & Human Performance, Adelaide, South Australia 5001
Country 149794 0
Australia
Phone 149794 0
+61 8 83021033
Fax 149794 0
Email 149794 0
Contact person for public queries
Name 149795 0
Karen Murphy
Address 149795 0
Adelaide University, Allied Health & Human Performance, Adelaide, South Australia 5001
Country 149795 0
Australia
Phone 149795 0
+61 8 83021033
Fax 149795 0
Email 149795 0
Contact person for scientific queries
Name 149796 0
Karen Murphy
Address 149796 0
Adelaide University, Allied Health & Human Performance, Adelaide, South Australia 5001
Country 149796 0
Australia
Phone 149796 0
+61 8 83021033
Fax 149796 0
Email 149796 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: MBCRC and Industry sponsor must provide permission to release results



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.